GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Syntara SNT.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.02

—

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Syntara — daily ASX:SNT

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Syntara on TradingView ↗
Market value
A$31.0m
Last close × shares
Volume
50.2k
Shares, 9 Nov 2026

About Syntara

Its shares trade on ASX under the ticker SNT.AX. It has been listed since 10 November 2003. In the fiscal year to 30 June 2025, it reported revenue of A$7.3m and a net loss of A$7.9m. At that date it held total assets of A$21.4m and shareholders' equity of A$16.0m.

Syntara Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. The company has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.

Figures and description from our data supplier, not checked against the company's own report.

More about Syntara →

Latest on Syntara

Our reporting

We have not reported on Syntara yet.

Next results

5 Feb 2027

Due on 5 Feb 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Syntara's ticker?

Syntara trades as SNT.AX on ASX, under ISIN AU0000312480.

What was Syntara's last closing price?

0.02 on 9 Nov 2026. The figure is in AUD and is never converted.

When does Syntara next report results?

Results are expected on 5 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.